Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Peacock
Fujisawa, Kanagawa, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
Peacock Therapeutics is a biotechnology company focused on developing next-generation ion channel modulators for the treatment of neurological disorders. The company's primary focus is on the KCNQ (Kv7) family of potassium channels, which play a critical role in regulating neuronal excitability. By utilizing a proprietary platform to identify highly selective small molecules, Peacock aims to address significant unmet needs in epilepsy and other hyperexcitability-related conditions. Their lead programs target KCNQ2/3 channels to provide precision medicine approaches for rare genetic epilepsies and broader seizure disorders.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Peacock.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peacock.